Mutations of Chromatin and its Modifying Machineries in Malignancies

恶性肿瘤中染色质及其修饰机制的突变

基本信息

  • 批准号:
    10518587
  • 负责人:
  • 金额:
    $ 94.5万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2015
  • 资助国家:
    美国
  • 起止时间:
    2015-08-13 至 2029-08-31
  • 项目状态:
    未结题

项目摘要

Project Summary Collective studies from my laboratory have focused on the molecular characterization of the function(s) and biochemical properties of the epigenetic modifiers and the mutations that are associated with human cancer. Our goal has been to determine how the mutations in these factors molecularly change the pattern of gene expression resulting in cellular hyperproliferation and use these molecular pathways to identify targeted therapeutics for cancer. Our detailed structural studies supported during the past seven years by this grant R35CA197569 have allowed us to identify the atomic structure of Set1/COMPASS, and based on this information, we have generated inhibitors towards its activity that are now being developed in our laboratory as a tool compound to regulate COMPASS's function in cells for the ultimate use in clinic. On other fronts, our analyses of the role of MLL3/COMPASS identified its interactions with the histone deubiquitinating enzyme BAP1, providing a central epigenetic balance at enhancers and the regulation of gene expression in cancer caused as the result of MLL3 mutations. Based on this information, we have a clinical trial at Northwestern Medicine investigating the epigenetic role of this balance in cancer therapy. We have also generated BAP1 inhibitors that can regulate hyperactivated BAP1 function in cancers caused as the result of ASXL1 mutations and such BAP1 inhibitors are being further investigated in our laboratory as biochemical and clinical tools. Our detailed analysis of the role of histone H3K27M mutations in diffuse intrinsic pontine gliomas (DIPG) resulted in the identification of a role for BET-domain containing factors such as Brd2 and Brd4 in DIPG pathogenesis. We are collaborating with colleagues at Lurie Children's Hospital of Chicago to test these findings in clinic. These studies also resulted in the identification of CATACOMB as an endogenous factor mimicking H3K27M and regulating PRC2 function. As will be described in the application, other studies in the laboratory have probed the mechanistic properties of diverse epigenetic factors in developmental regulation and in cancer. Additionally, recent cataloging of somatic mutations in cancer and during natural aging has identified a large number of mutations in the components of the MLL1-4, UTX, Set1A/B, and other epigenetic factors. Given that we have developed a fantastic set of reagents and tools over the past twenty years in our laboratory towards these factors, their associated proteins, chromatin, and other chromatin modifiers in multiple model systems, my laboratory is in a very unique and strong position to define the molecular bases of these factors’ involvement in cancer pathogenesis, and thus, for the purpose of targeted therapeutics. The goals of this R35 renewal application are the continuation of our full molecular and biochemical characterization of the trithorax COMPASS family and BAP1 complexes in the regulation of developmental gene expression, and how their mutations contribute to the pathogenesis of human cancer.
项目摘要 我实验室的集体研究集中在功能的分子表征上, 表观遗传修饰物的生物化学性质和与人类癌症相关的突变。 我们的目标是确定这些因子的突变如何在分子上改变基因的模式, 表达导致细胞过度增殖,并使用这些分子途径来鉴定靶向的 癌症的治疗方法。我们在过去七年中获得这笔赠款支持的详细结构研究 R35 CA 197569允许我们识别Set 1/COMPASS的原子结构,并基于此 信息,我们已经产生了针对其活性的抑制剂,目前正在我们的实验室中开发, 调节COMPASS在细胞中功能的工具化合物,最终用于临床。在其他方面, 对MLL 3/COMPASS作用的分析表明它与组蛋白去泛素化酶相互作用 BAP 1,在增强子处提供中心表观遗传平衡并调节癌症中的基因表达 这是MLL 3突变的结果。基于这些信息,我们在西北大学进行了一项临床试验 研究这种平衡在癌症治疗中的表观遗传作用的医学。我们还生成了BAP 1 抑制剂,可以调节由于ASXL 1突变引起的癌症中过度活化的BAP 1功能 我们的实验室正在进一步研究这种BAP 1抑制剂作为生物化学和临床工具。我们 详细分析组蛋白H3 K27 M突变在弥漫性内在脑桥胶质瘤(DIPG)中的作用, 鉴定含BET结构域的因子如Brd 2和Brd 4在DIPG发病机制中的作用。我们 正在与芝加哥卢里儿童医院的同事合作,在临床上测试这些发现。这些 研究还鉴定了CATACOMB作为模拟H3 K27 M的内源性因子, 调节PRC 2功能。如本申请中将描述的,实验室中的其他研究已经探索了 在发育调节和癌症中不同表观遗传因素的机械特性。此外,本发明还 最近对癌症和自然衰老过程中的体细胞突变的编目已经确定了大量的 MLL 1 -4、UTX、Set 1A/B和其他表观遗传因子的组分中的突变。鉴于我们有 在过去的二十年里,我们在实验室里针对这些因素开发了一套很棒的试剂和工具, 他们的相关蛋白质,染色质和其他染色质修饰剂在多个模型系统,我的实验室是 在确定这些因素参与癌症的分子基础方面处于非常独特和强有力的地位 发病机理,并因此用于靶向治疗的目的。此R35更新应用程序的目标 是我们对三胸龟COMPASS的完整分子和生物化学表征的延续 家族和BAP 1复合物在发育基因表达调控中的作用,以及它们如何 突变有助于人类癌症的发病机制。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(4)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Ali Shilatifard其他文献

Ali Shilatifard的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Ali Shilatifard', 18)}}的其他基金

Epigenetics, Metabolism and Cancer
表观遗传学、新陈代谢和癌症
  • 批准号:
    10712221
  • 财政年份:
    2023
  • 资助金额:
    $ 94.5万
  • 项目类别:
Mutations of Chromatin and its Modifying Machineries in Malignancies
恶性肿瘤中染色质及其修饰机制的突变
  • 批准号:
    10705758
  • 财政年份:
    2015
  • 资助金额:
    $ 94.5万
  • 项目类别:
Mutations of Chromatin and its Modifying Machineries in Malignancies
恶性肿瘤中染色质及其修饰机制的突变
  • 批准号:
    9126472
  • 财政年份:
    2015
  • 资助金额:
    $ 94.5万
  • 项目类别:
Mutations of Chromatin and its Modifying Machineries in Malignancies
恶性肿瘤中染色质及其修饰机制的突变
  • 批准号:
    10224897
  • 财政年份:
    2015
  • 资助金额:
    $ 94.5万
  • 项目类别:
Mutations of Chromatin and its Modifying Machineries in Malignancies
恶性肿瘤中染色质及其修饰机制的突变
  • 批准号:
    9754580
  • 财政年份:
    2015
  • 资助金额:
    $ 94.5万
  • 项目类别:
The COMPASS family of H3K4 methylases in development and cancer
H3K4 甲基化酶 COMPASS 家族在发育和癌症中的作用
  • 批准号:
    8759914
  • 财政年份:
    2010
  • 资助金额:
    $ 94.5万
  • 项目类别:
Mammalian H3K4 Methylases, Chromosomal Translocations and Human Leukemia
哺乳动物 H3K4 甲基化酶、染色体易位和人类白血病
  • 批准号:
    8403710
  • 财政年份:
    2010
  • 资助金额:
    $ 94.5万
  • 项目类别:
Mammalian H3K4 Methylases, Chromosomal Translocations and Human Leukemia
哺乳动物 H3K4 甲基化酶、染色体易位和人类白血病
  • 批准号:
    8595296
  • 财政年份:
    2010
  • 资助金额:
    $ 94.5万
  • 项目类别:
Mammalian H3K4 Methylases, Chromosomal Translocations and Human Leukemia
哺乳动物 H3K4 甲基化酶、染色体易位和人类白血病
  • 批准号:
    8204739
  • 财政年份:
    2010
  • 资助金额:
    $ 94.5万
  • 项目类别:
Mammalian H3K4 Methylases, Chromosomal Translocations and Human Leukemia
哺乳动物 H3K4 甲基化酶、染色体易位和人类白血病
  • 批准号:
    8041000
  • 财政年份:
    2010
  • 资助金额:
    $ 94.5万
  • 项目类别:

相似海外基金

CAREER: Biochemical and Structural Mechanisms Controlling tRNA-Modifying Metalloenzymes
职业:控制 tRNA 修饰金属酶的生化和结构机制
  • 批准号:
    2339759
  • 财政年份:
    2024
  • 资助金额:
    $ 94.5万
  • 项目类别:
    Continuing Grant
Leveraging releasable aryl diazonium ions to probe biochemical systems
利用可释放的芳基重氮离子探测生化系统
  • 批准号:
    2320160
  • 财政年份:
    2023
  • 资助金额:
    $ 94.5万
  • 项目类别:
    Standard Grant
Diurnal environmental adaptation via circadian transcriptional control based on a biochemical oscillator
基于生化振荡器的昼夜节律转录控制的昼夜环境适应
  • 批准号:
    23H02481
  • 财政年份:
    2023
  • 资助金额:
    $ 94.5万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Systematic manipulation of tau protein aggregation: bridging biochemical and pathological properties
tau 蛋白聚集的系统操作:桥接生化和病理特性
  • 批准号:
    479334
  • 财政年份:
    2023
  • 资助金额:
    $ 94.5万
  • 项目类别:
    Operating Grants
Converting cytoskeletal forces into biochemical signals
将细胞骨架力转化为生化信号
  • 批准号:
    10655891
  • 财政年份:
    2023
  • 资助金额:
    $ 94.5万
  • 项目类别:
Enhanced Biochemical Monitoring for Aortic Aneurysm Disease
加强主动脉瘤疾病的生化监测
  • 批准号:
    10716621
  • 财政年份:
    2023
  • 资助金额:
    $ 94.5万
  • 项目类别:
Biochemical Mechanisms for Sustained Humoral Immunity
持续体液免疫的生化机制
  • 批准号:
    10637251
  • 财政年份:
    2023
  • 资助金额:
    $ 94.5万
  • 项目类别:
Structural and biochemical investigations into the mechanism and evolution of soluble guanylate cyclase regulation
可溶性鸟苷酸环化酶调节机制和进化的结构和生化研究
  • 批准号:
    10604822
  • 财政年份:
    2023
  • 资助金额:
    $ 94.5万
  • 项目类别:
Chemical strategies to investigate biochemical crosstalk in human chromatin
研究人类染色质生化串扰的化学策略
  • 批准号:
    10621634
  • 财政年份:
    2023
  • 资助金额:
    $ 94.5万
  • 项目类别:
EAGER: Elastic Electronics for Sensing Gut Luminal and Serosal Biochemical Release
EAGER:用于感测肠腔和浆膜生化释放的弹性电子器件
  • 批准号:
    2334134
  • 财政年份:
    2023
  • 资助金额:
    $ 94.5万
  • 项目类别:
    Standard Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了